FDA Begins Safety Review of Bleeding Events With Boehringer’s Pradaxa

Drug Industry Daily
The FDA is reviewing postmarket reports of serious bleeding events in patients taking Boehringer Ingelheim’s blood-thinner Pradaxa just as the drug is facing increased competition with approval of Johnson & Johnson and Bayer’s Xarelto in atrial fibrillation (AF) patients.

To View This Article:


Subscribe To Drug Industry Daily